CN113164584A - 免疫原性组合物及其用途 - Google Patents

免疫原性组合物及其用途 Download PDF

Info

Publication number
CN113164584A
CN113164584A CN201980068212.4A CN201980068212A CN113164584A CN 113164584 A CN113164584 A CN 113164584A CN 201980068212 A CN201980068212 A CN 201980068212A CN 113164584 A CN113164584 A CN 113164584A
Authority
CN
China
Prior art keywords
self
antigen
replicating rna
rna molecule
influenza
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980068212.4A
Other languages
English (en)
Chinese (zh)
Inventor
S·贝尔托莱特吉拉丁
A·库马尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Publication of CN113164584A publication Critical patent/CN113164584A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CN201980068212.4A 2018-08-17 2019-08-16 免疫原性组合物及其用途 Pending CN113164584A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862719219P 2018-08-17 2018-08-17
US62/719219 2018-08-17
PCT/EP2019/072052 WO2020035609A2 (en) 2018-08-17 2019-08-16 Immunogenic compositions and uses thereof

Publications (1)

Publication Number Publication Date
CN113164584A true CN113164584A (zh) 2021-07-23

Family

ID=67766133

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980068212.4A Pending CN113164584A (zh) 2018-08-17 2019-08-16 免疫原性组合物及其用途

Country Status (7)

Country Link
US (2) US12083174B2 (cg-RX-API-DMAC7.html)
EP (1) EP3836963A2 (cg-RX-API-DMAC7.html)
JP (1) JP2021534182A (cg-RX-API-DMAC7.html)
CN (1) CN113164584A (cg-RX-API-DMAC7.html)
AU (1) AU2019321186B2 (cg-RX-API-DMAC7.html)
CA (1) CA3109165A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020035609A2 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3727444A1 (en) 2017-12-18 2020-10-28 Intervet International B.V. Swine influenza a virus vaccine
JP2023517644A (ja) 2020-03-09 2023-04-26 アークトゥラス・セラピューティクス・インコーポレイテッド コロナウイルスワクチン組成物及び方法
JP2023521662A (ja) 2020-04-03 2023-05-25 グリットストーン バイオ インコーポレイテッド 感染症抗原及びワクチン
IL298363A (en) * 2020-05-20 2023-01-01 Flagship Pioneering Innovations Vi Llc Immunogenic compositions and uses thereof
EP4168044A1 (en) 2020-06-19 2023-04-26 Intervet International B.V. Swine influenza a virus vaccine comprising two distinct rna replicon particles
US12178921B2 (en) 2020-08-14 2024-12-31 Arcturus Therapeutics, Inc. Method of lyophilizing lipid nanoparticles
MX2023004371A (es) 2020-10-14 2023-07-26 George Mason Res Foundation Inc Lípidos ionizables, y métodos de fabricación y uso de los mismos.
AU2021392077A1 (en) * 2020-12-02 2023-07-13 Seqirus Inc. Multicistronic rna vaccines and uses thereof
EP4313152A1 (en) * 2021-03-26 2024-02-07 GlaxoSmithKline Biologicals S.A. Immunogenic compositions
US20240238404A1 (en) * 2021-05-19 2024-07-18 Daiichi Sankyo Company, Limited Influenza virus nucleic acid lipid particle vaccine
AU2022396547A1 (en) * 2021-11-29 2024-06-06 Replicate Bioscience, Inc. Methods of generating self-replicating rna molecules
WO2023213378A1 (en) * 2022-05-02 2023-11-09 BioNTech SE Replicon compositions and methods of using same for the treatment of diseases
US20240009296A1 (en) * 2022-07-10 2024-01-11 Pfizer Inc. Self-amplifying rna encoding an influenza virus antigen
TW202438672A (zh) * 2023-01-31 2024-10-01 美商亞克圖羅斯醫療公司 四價流感疫苗之方法及組成物
EP4661903A1 (en) * 2023-02-09 2025-12-17 Pfizer Inc. Nucleic acids and uses thereof
WO2024254461A2 (en) * 2023-06-07 2024-12-12 Nutech Ventures Methods and compositions for vaccine development and delivery
WO2024261648A1 (en) * 2023-06-19 2024-12-26 Seqirus Inc. Multivalent subtype influenza vaccine
CN117205309B (zh) * 2023-11-07 2024-02-02 今发制药(南京)有限公司 一种流感免疫原组合物和制备方法及其用途
WO2025210141A1 (en) * 2024-04-05 2025-10-09 Boehringer Ingelheim Vetmedica Gmbh Delivery system useful for topical administration of rna

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110300205A1 (en) * 2009-07-06 2011-12-08 Novartis Ag Self replicating rna molecules and uses thereof
WO2013006842A2 (en) * 2011-07-06 2013-01-10 Novartis Ag Immunogenic compositions and uses thereof
US20140212498A1 (en) * 2011-07-06 2014-07-31 Luis Brito Oil-in-water emulsions that contain nucleic acids
US20140271829A1 (en) * 2011-10-11 2014-09-18 Anders Lilja Recombinant self-replicating polycistronic rna molecules
CN104902925A (zh) * 2013-01-10 2015-09-09 诺华股份有限公司 流感病毒免疫原性组合物及其应用
CN106822887A (zh) * 2017-01-26 2017-06-13 中国科学院微生物研究所 一种流感病毒四价亚单位疫苗及其应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5132418A (en) 1980-02-29 1992-07-21 University Patents, Inc. Process for preparing polynucleotides
US4500707A (en) 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4668777A (en) 1981-03-27 1987-05-26 University Patents, Inc. Phosphoramidite nucleoside compounds
US4973679A (en) 1981-03-27 1990-11-27 University Patents, Inc. Process for oligonucleo tide synthesis using phosphormidite intermediates
US4373071A (en) 1981-04-30 1983-02-08 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US5153319A (en) 1986-03-31 1992-10-06 University Patents, Inc. Process for preparing polynucleotides
US5047524A (en) 1988-12-21 1991-09-10 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5262530A (en) 1988-12-21 1993-11-16 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5700642A (en) 1995-05-22 1997-12-23 Sri International Oligonucleotide sizing using immobilized cleavable primers
PT1751289E (pt) 2004-05-18 2009-03-31 Alphavax Inc Vectores de alfavirais derivados da tc-83, partículas e métodos
WO2011076807A2 (en) 2009-12-23 2011-06-30 Novartis Ag Lipids, lipid compositions, and methods of using them
FI4005592T3 (fi) 2010-07-06 2023-01-13 Virionin kaltaisia kuljetuspartikkeleita itsereplikoituville rna-molekyyleille
CN103153284B (zh) 2010-07-06 2015-11-25 诺华股份有限公司 含有其pKa值有利于RNA递送的脂质的脂质体
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
CA2804591C (en) 2010-07-06 2019-01-22 Novartis Ag Cationic oil-in-water emulsions
JP5911870B2 (ja) 2010-08-31 2016-04-27 ノバルティス アーゲー 免疫原をコードするrnaの送達のためのpeg化リポソーム
RS63890B1 (sr) 2010-08-31 2023-02-28 Glaxosmithkline Biologicals Sa Mali lipozomi za isporuku rnk koja kodira imunogen
EP3542789A3 (en) 2010-08-31 2020-01-01 GlaxoSmithKline Biologicals SA Lipids suitable for liposomal delivery of protein-coding rna
US9636410B2 (en) 2011-07-06 2017-05-02 Glaxosmithkline Biologicals Sa Cationic oil-in-water emulsions
RU2014104090A (ru) 2011-07-06 2015-08-20 Новартис Аг Липосомы с эффективным соотношением n:p для доставки молекул phk
PT2750707T (pt) 2011-08-31 2019-01-23 Glaxosmithkline Biologicals Sa Lipossomas peguilados para distribuição de arn que codifica imunogénio
ES2887254T3 (es) 2013-03-08 2021-12-22 Novartis Ag Lípidos y composiciones lipídicas para el suministro de agentes activos
US10059655B2 (en) 2013-12-19 2018-08-28 Novartis Ag Lipids and lipid compositions for the delivery of active agents
US10426737B2 (en) 2013-12-19 2019-10-01 Novartis Ag Lipids and lipid compositions for the delivery of active agents
ES2969956T3 (es) 2014-09-05 2024-05-23 Novartis Ag Lípidos y composiciones lipídicas para el suministro de agentes activos
US10022436B2 (en) * 2016-01-11 2018-07-17 Verndari, Inc. Microneedle compositions and methods of using same

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110300205A1 (en) * 2009-07-06 2011-12-08 Novartis Ag Self replicating rna molecules and uses thereof
WO2013006842A2 (en) * 2011-07-06 2013-01-10 Novartis Ag Immunogenic compositions and uses thereof
US20140212498A1 (en) * 2011-07-06 2014-07-31 Luis Brito Oil-in-water emulsions that contain nucleic acids
US20140271829A1 (en) * 2011-10-11 2014-09-18 Anders Lilja Recombinant self-replicating polycistronic rna molecules
CN104902925A (zh) * 2013-01-10 2015-09-09 诺华股份有限公司 流感病毒免疫原性组合物及其应用
CN106822887A (zh) * 2017-01-26 2017-06-13 中国科学院微生物研究所 一种流感病毒四价亚单位疫苗及其应用

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DILETTA MAGINI ET AL.,: ""Self-Amplifying mRNA Vaccines Expressing Multiple Conserved Influenza Antigens Confer Protection against Homologous and Heterosubtypic Viral Challenge"", 《PLOS ONE》, vol. 11, no. 8, pages 3 - 4 *
FRANCESCO BERLANDA SCORZA ET AL.,: ""New Kids on the Block: RNA-Based Influenza Virus Vaccines"", 《VACCINES》, vol. 6, no. 2, pages 4 - 5 *
KENNETH LUNDSTROM ET AL.,: ""Replicon RNA Viral Vectors as Vaccines"", 《VACCINES》, vol. 4, no. 4, pages 39, XP055552221, DOI: 10.3390/vaccines4040039 *
LUIS A BRITO ET AL.,: ""A Cationic Nanoemulsion for the Delivery of Next-generation RNA Vaccines"", 《THE AMERICAN SOCIETY OF GENE & CELL THERAPY》, vol. 22, no. 12, pages 2118 - 2129, XP055180488, DOI: 10.1038/mt.2014.133 *
V. TISA ET AL.,: ""Quadrivalent influenza vaccine: a new opportunity to reduce the influenza burden"", 《J PREV MED HYG》, vol. 57, no. 1, pages 28 *
VOGEL ET AL.,: ""Self-Amplifying RNA Vaccines Give Equivalent Protection against Influenza to mRNA Vaccines but at Much Lower Doses"", 《MOLECULAR THERAPY》, vol. 26, no. 2, XP055643534, DOI: 10.1016/j.ymthe.2017.11.017 *

Also Published As

Publication number Publication date
AU2019321186B2 (en) 2024-05-23
US20250064916A1 (en) 2025-02-27
AU2019321186A1 (en) 2021-02-18
CA3109165A1 (en) 2020-02-20
US20210252133A1 (en) 2021-08-19
US12083174B2 (en) 2024-09-10
WO2020035609A2 (en) 2020-02-20
WO2020035609A3 (en) 2020-05-28
EP3836963A2 (en) 2021-06-23
JP2021534182A (ja) 2021-12-09

Similar Documents

Publication Publication Date Title
US20250064916A1 (en) Immunogenic compositions and uses thereof
US10967057B2 (en) Zika viral antigen constructs
US20220241398A1 (en) Lyssavirus antigen constructs
US11780885B2 (en) Zika viral antigen constructs
US20240181038A1 (en) Immunogenic compositions
US20230234992A1 (en) Modified betacoronavirus spike proteins
KR20250075664A (ko) 인플루엔자 바이러스 백신
US20240301006A1 (en) Self-amplifying messenger rna
EP3522919B1 (en) Vaccine
JP2026514290A (ja) 核酸およびその使用
WO2024223728A1 (en) Influenza virus vaccines

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20210723

RJ01 Rejection of invention patent application after publication